Outcomes of Consolidative Allogeneic Transplantation After Venetoclax Plus Hypomethylating Agent Induction in Acute Myeloid Leukemia: A Single-Center Retrospective Study (SOHO 2026) - Sep 1, 2026 - Abstract #AML-998; Location: LEVEL 3, HALL B3; "Induction consisted of VEN with 5-day decitabine (DEC) (VEN7/14-DEC5; n = 16, 66.7%) or 7-day azacitidine (VEN7/14-AZA7; n = 8, 33.3%), with a median of 2 cycles (range, 1–4) before allo-HSCT...One patient received ponatinib maintenance... In our cohort, allo-HSCT after VEN+HMA bridging demonstrated favorable outcomes despite a substantial proportion of patients being MRD-positive prior to transplantation. Transplantrelated mortality and graft-versus-host disease remain the key challenges. CR: complete response, CRi: CR with incomplete hematologic recovery, ECOG: Eastern Cooperative Oncology Group, ELN: European LeukemiaNet, GVHD: graft-versus-host disease, MAC: myeloablative conditioning, MFC: multiparameter flow cytometry, MLFS: morphologic leukemia-free state, MRD: minimal residual disease, MSD: matched sibling donors, RIC: reduced-intensity conditioning."
Retrospective data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
|
|
Milvydė Tamutytė-Jankauskė 1,2; Milda Mikalonytė 1,2; Tautvilė Smalinskaitė 1,2; Guoda Daukėlaitė 1,2; Lukas Kevličius 1; Linas Davainis 1; Igoris Trociukas 1; Artūras Slobinas 1; Renata Jucaitienė 1; Inga Šlepikienė 1; Rita Kviliūtė 1; Raminta Batiuškaitė 1; Laimonas Griškevičius 1,2; Andrius Žučenka 1,2
|